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The impact of PICALM genetic 
variations on reserve capacity of 
posterior cingulate in AD continuum
Wei Xu1,*, Hui-Fu Wang2,*, Lin Tan3, Meng-Shan Tan1, Chen-Chen Tan1, Xi-Chen Zhu2,   
Dan Miao1, Wan-Jiang Yu4, Teng Jiang5, Lan Tan1,2,3, Jin-Tai Yu1 & Alzheimer’s Disease 
Neuroimaging Initiative Group# 
Phosphatidylinositolbinding clathrin assembly protein (PICALM) gene is one novel genetic 
player associated with late-onset Alzheimer’s disease (LOAD), based on recent genome wide 
association studies (GWAS). However, how it affects AD occurrence is still unknown. Brain 
reserve hypothesis highlights the tolerant capacities of brain as a passive means to fight 
against neurodegenerations. Here, we took the baseline volume and/or thickness of LOAD-
associated brain regions as proxies of brain reserve capacities and investigated whether 
PICALM genetic variations can influence the baseline reserve capacities and the longitudinal 
atrophy rate of these specific regions using data from Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) dataset. In mixed population, we found that brain region significantly 
affected by PICALM genetic variations was majorly restricted to posterior cingulate. In 
sub-population analysis, we found that one PICALM variation (C allele of rs642949) was 
associated with larger baseline thickness of posterior cingulate in health. We found seven 
variations in health and two variations (rs543293 and rs592297) in individuals with mild 
cognitive impairment were associated with slower atrophy rate of posterior cingulate. Our 
study provided preliminary evidences supporting that PICALM variations render protections 
by facilitating reserve capacities of posterior cingulate in non-demented elderly.
The global situation of dementia is not optimistic. The prevalence of dementia was estimated 5–7% in most global 
regions and 35.6 million people lived with dementia in 2010, with numbers predicted to almost double every 
20 years, to 65.7 million in 2030 and 115.4 million in 20501,2, leading to an increasing burden on caregivers and 
society3. The recently released Alzheimer Report 2015 reflects a same trend but lousier prospect. (http://www.
alzforum.org/news/research-news/world-alzheimer-report-2015-revised-estimates-hint-larger-epidemic) As 
the most common type (roughly 60%) of dementia, Alzheimer’s disease (AD) significantly inflicts both reduced 
life-span and lowered life quality on patients4–6.
In confrontation of this situation, scientific efforts to elucidate its etiology has never been stopped. It is now 
widely accepted that AD is a complex disease entity, with occurrence underpinned by both genetic and environ-
mental components7,8. APOE4 was a widely validated genetic risk but merely accounted for a limited percentage 
of LOAD risk, several genome-wide association studies (GWAS) and meta-analyses had revealed a series of new 
risk loci associated with the late-onset type of AD (LOAD; > 65 years of age)9–12, to some extent filling up the 
vacant area of its genetic etiology.
The gene encoding phosphatidylinositolbinding clathrin assembly protein (PICALM) was one of these new 
players. Its association with AD was revealed in large GWAS9–12 and further validated in a series of larger repli-
cation studies in both European13–17 and Asian population18, in spite of some conflicting results from those with 
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smaller sample sizes19. However, the concrete pathways by which PICALM gene are involved in AD occurrence 
are still an enigma.
More than a decade ago, Stern20,21 proposed the concept of reserve to explain the disjunction between AD 
pathology degree and severity of clinical performances. The hypothesis proposed a passive protective model 
named “brain reserve”, positing that the quantity of available neural substrate (e.g., brain size, synaptic count, or 
dendritic branching) can be the basis of cerebral tolerance to abnormal insults (Fig. 1A)8,22. However, it seemed 
that previous understandings put more focus on the global situation of the whole brain than on some brain 
regions specifically associated with the disease, such as hippocampus (CA1 subregion), middle temporal area, 
entorhinal area, posterior cingulate, precuneus, and parahippocampal area. Based on these findings, we thus 
supposed that LOAD-associated genetic variations may be involved in AD occurrence by modulating the brain 
reserve capacities of these brain sub-regions which has been proved vulnerable in AD process (Fig. 1B).
Herein, we took the baseline volume and/or thickness of AD-associated brain regions (as mentioned above) 
as proxies of brain reserve capacities and investigated whether PICALM genetic variations can influence the 
reserve capacities and longitudinal atrophy rate of these specific regions using data from Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) dataset.
Results
Demographic, cognitive, and clinical characteristics. Demographic, cognitive, and clinical charac-
teristics of the included subjects are shown in Table 1. In brief, a total of 281 NC (145 female, 74.51 ± 5.56 years), 
483 MCI (201 female, 72.28 ± 7.45 years) and 48 AD patients (18 female, 75.51 ± 9.23 years) were enrolled in the 
present study. The frequency for the ε 4 allele of APOE gene was AD > MCI > NC. For the cognitive function, AD 
patients displayed the worst cognitive function according to various neuropsychological scales, including CDRSB, 
MMSE, ADAS-cog, RAVLT, FAQ and MoCA. For the brain reserve capacity, AD patients showed the most severe 
atrophy in hippocampus, middle temporal and entorhinal cortex.
Brain structures and PICALM genotypes in the mixed population. At baseline, no loci showed 
significant association with volume of either hippocampus or hippocampal CA1 region. A allele of rs3851179 
showed trend of association with larger thickness of right entorhinal area. G allele of rs561655 showed trend of 
association with larger thickness of parahippocampal region. C allele of rs592297 showed trend of association 
with smaller volume of left middle temporal area and larger thickness of parahippocampal region. C allele of 
rs642949 showed trends of association with larger volume of left middle temporal area and right posterior cin-
gulate, larger thickness of left precuneus and smaller thickness of left parahippocampal area. However, all these 
associations failed to survive the FDR correction (Fig. 2 and Supplementary Table 2).
Analysis after one year follow-up indicated faster atrophy rate of right hippocampal CA1 for individuals car-
rying variations in rs543293 (A allele) and rs1237999 (G allele). C allele of rs64249 showed trends of associa-
tions with slower atrophy rate of left hippocampus and faster atrophy rate of right precuneus. Nonetheless, these 
associations did not reach significant after FDR correction. Interestingly, we found slower atrophy rate of right 
posterior cingulate in individuals with variations of rs561655 (G allele), rs543293 (A allele), rs592297 (C allele), 
Figure 1. (A) Depiction of how brain reserve operates to protect the brain. The x-axis represents time, over 
which AD pathology slowly accumulates. The y-axis represents cognitive function. We assume that AD pathology 
accumulates over time at the same rate in two individuals with high and low brain reserve (BR). The amount 
of pathology needed before cognitive function is affected is greater for individual with higher CR, leading to a 
later change point of time. It follows that greater pathology will be needed for the person with higher BR to meet 
clinical diagnostic criteria for AD, thus delaying the onset of the disease. Once cognitive decline arises, it is faster 
in the person with higher BR22. (B) We proposed a hypothesis that PICALM genetic variations were associated 
with brain reserve (baseline thickness/volume and atrophy rate) of specific regions associated with AD in non-
dementia elderly. We hypothesized that individuals carrying specific PICALM variations might have higher 
baseline thickness/volume of specific brain areas and/or slower atrophy rate in confrontation with impacts of 
pathological impairments and/or normal aging for some unknown reasons. Based on model depicted in (A), 
these trends equivalently render two powerful “weapons” for the individuals to maintain normal cognition and 
stay away from AD over a period longer than others. Abbreviation: BR = brain reserve; AD = Alzheimer’s disease.
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rs1237999 (G allele) and 7941541 (G allele) and faster atrophy rate of the same region in individuals with varia-
tion of rs642949 (C allele) The associations were still significant after FDR correction (Fig. 3A–F).
After two years follow-up, no loci showed significant association with atrophy rate of hippocampus or hip-
pocampal CA1 region. Atrophy rate of middle temporal area showed trend of association with variation of 
rs642949. Atrophy rate of posterior cingulate showed trend of association with variation of rs3851179, rs543293, 
rs7941541, and rs642949. Atrophy rate of precuneus showed trend of association with variation of rs561655 
and rs642949. Atrophy rate of parahippocampal area showed trend of association with variation of rs642949. 
Characteristics NC MCI AD P*
Age (years) 281 74.51 ± 5.56 483 72.28 ± 7.45 48 75.51 ± 9.23 < 0.01
Gender (male/female) 281 136/145 483 282/201 48 30/18 0.02
Education (years) 281 16.41 ± 2.66 483 15.98 ± 2.82 48 15.73 ± 2.62 0.08
APOE ε 4 (0/1/2) 281 204/70/7 483 262/180/41 48 14/25/9 < 0.01 
CDR-SB 207 0.03 ± 0.13 406 1.44 ± 0.87 47 4.44 ± 1.69 < 0.01 
MMSE 281 29.07 ± 1.15 483 27.89 ± 1.69 48 22.96 ± 2.03 < 0.01 
ADAS-cog 281 9.06 ± 4.23 480 15.30 ± 6.65 48 29.80 ± 8.44 < 0.01 
RAVLT 280 44.83 ± 9.60 483 36.16 ± 10.86 47 22.32 ± 7.84 < 0.01 
FAQ 281 0.17 ± 0.66 481 2.85 ± 3.99 48 12.6 ± 7.14 < 0.01 
Hippocampus (mm3) 257 7344 ± 895 422 6996 ± 1126 39 5757 ± 948 < 0.01
Middle Temporal (mm3) 257 20298 ± 2600 422 20186 ± 2735 39 17776 ± 3230 < 0.01
Entorhinal (mm3) 257 3803 ± 650 422 3610 ± 723 39 2919 ± 705 < 0.01
CMRgl 207 6.55 ± 0.55 406 6.32 ± 0.64 47 5.30 ± 0.72 < 0.01
SUVR 152 1.12 ± 0.19 323 1.20 ± 0.22 46 1.39 ± 0.22 < 0.01
Table 1.  The characteristics of the ADNI subjects at baseline. NC, normal cognition; MCI, mild cognition 
impairment; AD, Alzheimer’s disease; CDR-SB, Clinical Dementia Rating sum of boxes; ADAS-cog, Alzheimer’s 
disease Assessment Scale Cognition; MMSE, Mini-Mental State Exam; RAVLT, Rey Auditory Verbal Learning 
Test; FAQ, Functional Activities Questionnaire; CMRgl, Cerebral Metabolism Rate for glucose measured with 
fluorodeoxyglucose-positron emission tomography (FDG-PET). SUVR, florbetapir standard uptake value 
ratios on amyloid imaging. *P values for continuous variables are from one-way analysis of variance (ANOVA). 
P values for categorical data are from chi square test. Data are given as mean ± standard deviation unless 
otherwise indicated.
Figure 2. The procedure and gross results of associations analysis in mixed population and sub-population 
(NC and MCI). In mixed population, we identified multiple brain regions showing trend of association with 
PICALM genetic variations (Deep green block). However, only posterior cingulate survived the FDR correction 
(Red block); We further tested this genetic predisposition in NC and MCI population. Results in NC individuals 
indicated that variations of seven loci were associated with baseline or one year or two years atrophy rate of 
posterior cingulate; Results in MCI individuals indicated that variations of two loci were associated with one 
year or two years atrophy rate of posterior cingulate. Abbreviations: NC = normal cognition; MCI = mild 
cognition impairment; AD = Alzheimer’s disease.
www.nature.com/scientificreports/
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Nonetheless, none of these reached significance after FDR correction, possibly due to the shrunken sample size 
after two years follow-up (Fig. 2 and Supplementary Table 2).
Altogether, we can infer that posterior cingulate may be the pivotal region on which PICALM variations 
target. Further, we selected the posterior cingulate as our sole ROI and independently tested its association with 
PICALM variations in NC and MCI individuals, respectively.
Posterior cingulate and PICALM genotypes in NC individuals. The associations of variations in four 
PICALM loci (rs561655, rs1237999, rs543293 and rs592297) with slower one-year atrophy rate of posterior cingu-
late were further validated in the NC population (Fig. 4B–F). Interestingly, we found that one PICALM variation 
(C allele of rs642949) was associated with larger thickness of posterior cingulate at baseline (Fig. 4A). We found 
significant association of rs561655, rs7941541 and rs3851179 with slower two years atrophy rate of posterior cin-
gulate (Fig. 4G–I). This is expectable since the major contributors to brain atrophy and atrophy rate differ between 
NC individuals and MCI/AD individuals, such that the overall atrophy rate of posterior cingulate in the mixed 
population (NC+ MCI+ AD) was faster than that in the NC population (Fig. 4L).
Posterior cingulate and PICALM genotypes in MCI individuals. Compared to NC population, the 
trend of associations of PICALM variations with atrophy rate of posterior cingulate in MCI population were con-
sistent (Fig. 2). We found A allele of rs543293 and C allele of rs592297 were associated with slower atrophy rate 
(after one year and two years) of posterior cingulate, respectively (Fig. 4J,K).
Posterior cingulate and PICALM genotypes in AD individuals. We failed to identify any significant 
associations of reserve capacities of posterior cingulate with PICALM variations in AD population, possibly due 
to the constrained sample size.
Discussion
We present here an explorative study about how single nucleotide polymorphisms of PICALM impart influences 
on brain reserve capacity of AD-associated brain regions. Seven SNPs were finally included in the analysis. We 
found six loci (all except rs3851179) in mixed population, two loci (rs592297 and rs543293) in MCI population 
and all seven loci in NC population, which were significantly associated with higher baseline thickness and/or 
slower atrophy rate of posterior cingulate, both of which would be favorable in fighting against AD insults, despite 
in a passive manner (Fig. 1B) These findings were significant given that 1) our study further revealed the poten-
tial pathways by which these genetic variations act in protecting brain from AD; 2) Our findings confirmed the 
protective roles of certain loci of PICALM gene, which is consistent with previous meta-analysis results of associ-
ation of AD with rs561655 (odd ratio [OR] = 0.87; 95% confidence interval [95% CI] = 0.83–0.92) and rs543293 
(OR = 0.89; 95% CI = 0.85–0.94). (http://www.alzgene.org/meta.asp?geneID= 636)
Though our study showed that PICALM variations were associated with higher brain reserve capacities of 
posterior cingulate, the mechanism was still a mystery. Generally, the major contributors to brain atrophy include 
Figure 3. The significant associations of PICALM loci with atrophy rate of posterior cingulate in the mixed 
population. We identified six loci which associations were still significant after FDR correction in the mixed 
population. The (A–F) depicted that variations of rs1237999, rs642949, rs561655, rs543293, rs7941541 and 
rs592297 were associated with one-year atrophy rate of posterior cingulate.
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normal aging in which the process is relatively slower and stable, as well as abnormal pathological insults in which 
the process is relatively faster and changeable. In NC individuals, cerebral resistance power is enough to tolerate 
these two adverse contributors, thus contributing to the normal cognitive functions. Although we know little 
about which contributor held a dominant position in inducing brain atrophy in the NC stage, it is reasonably 
inferred that the role of abnormal pathologies is increasingly rising and would finally surpass that of normal aging 
as the stage further progresses (for example, from NC to MCI/AD) (Fig. 4L). In the present analysis, we found 
that PICALM genetic variations were more inclined to be associated with atrophy rate in NC individuals. Given 
that normal aging might play a more important role in causing brain atrophy in the stage of NC than MCI/AD, it 
can be thus inferred that the potential pathways by which PICALM variations act may be possibly associated with 
fighting against normal aging of posterior cingulate. More researches warrant to validate this hypothesis.
On the other hand, posterior cingulate cortex is located in the medial part of the inferior parietal lobe and 
lies within the posteromedial cortex. This specific brain area is highly anatomically connected and is known as a 
pivotal part of the default mode network (DMN), which is a resting-state functional networks and is particularly 
active in healthy people when they do not think about anything (for review see23,24). Previous cross-sectional 
analysis suggested that both AD and MCI subjects showed significant difference of posterior cingulate when 
compared with the health25–27. Also, disorder of DMN was a characteristic feature seen in early AD24. All these 
findings were suggestive of an impellent role of neurodegeneration of posterior cingulate in the very early stage 
of AD28. Our study provided the first evidence linking PICALM genetic variations with slower atrophy rate of 
posterior cingulate, leading to a reasonable postulation that individuals carrying these specific variations would 
Figure 4. The significant associations of PICALM loci with baseline thickness and atrophy rate of 
posterior cingulate in health and MCI individuals. (A) Depicted that rs642949 (C allele) was associated 
with larger thickness of posterior cingulate in NC population; (B–I) Depicted that variations of rs561655, 
rs1237999, rs543293, rs592297, rs7941541 were associated with slower atrophy rate of posterior cingulate in NC 
population; (J,K) Depicted that rs543293 and rs592297 were associated with slower atrophy rate of posterior 
cingulate in MCI population. (L) Depicted that the contributors to brain atrophy majorly included normal 
aging and pathological insults. The proportion of the latter would arise constantly as the stage progresses (from 
NC to MCI to AD) and finally become the predominant factor. This may explain the difference of association 
which PICALM genetic variations showed in NC and MCI population. Abbreviations: NC = normal cognition; 
MCI = mild cognition impairment; AD = Alzheimer’s disease.
www.nature.com/scientificreports/
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be less vulnerable to lower reserve capacity of posterior cingluate and be possibly thus more powerful in fighting 
neurodegenerative insults.
Furthermore, as a critical network of brain, DMN was composed of large amounts of communication hubs 
named “synapses”. A very recent study proposed that DMN correlated with the orchestrated activity of dozens of 
genes linked to ion channel activity and synaptic function29, emphasizing the importance of synapses in main-
taining normal functions of this network. On the other hand, it was previously reported that abnormalities of 
synapses in posterior cingulate occurred in the early stage of AD30. Therefore, PICALM may protect the normal 
operations of synapse by facilitating neurotransmitter delivering, which is against the negative impacts derived 
from normal aging or pathological insults such as Aβ . (for review see31)
Several limitations exist in our study. First of all, the sample size in the present analysis was smaller than that 
in the traditional large GWAS studies (n > 10,000); Second, the follow-up was relatively short. Both of these lead 
to restricted power and thus restrain our making definite conclusions. Therefore, this study is only a preliminary 
investigation and future replication with larger sample size and longer follow-up is necessary. Third, not all SNPs 
of PICALM gene were included due to the restriction of ADNI database. Fourth, associations of PICALM gene 
with posterior cingulate in AD population need more work given the AD sample in our study is obviously con-
strained. These may lead to insufficient digging of influences of PICALM genetic variations and future research 
warrant. Fifth, it is noteworthy that the results from sub-population (NC or MCI or AD) may be more informative 
than those from mixed population, which lead to, again, necessities of future efforts with larger sample.
In summary, this study provided preliminary evidences supporting that PICALM variations render protec-
tions by facilitating reserve capacities of posterior cingulate in non-demented elderly.
Materials and Methods
Definition of brain reserve (BR). Brain reserve (BR) can be metaphorized as cerebral pre-existing troops 
(such as brain/specific brain region size, neuron/synaptic count, and dendritic branching, etc.), which are whole-
heartedly responsible for maintaining a normal cognitive function by passively defending against attacks from 
pathological insults (for example, Alzheimer’s disease) as well as normal aging. However, once the loss of these 
troops achieved a certain level (so-called threshold model), cognitive impairments occurred.
ADNI database. Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a large, multicenter, longitudinal 
neuroimaging study, initiated in 2003 by the National Institute on Aging, the National Institute of Biomedical 
Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and non-
profit organizations32. The initial goal of ADNI was to recruit 800 subjects but the ADNI has been further fol-
lowed by ADNI-GO and ADNI-2. To date, the three protocols have recruited over 1,500 adults (aged 55 to 90), 
consisting of cognitively normal older individuals, people with early or late MCI, and people with AD. The study 
was approved by the institutional review boards of all participating centers, and written informed consent was 
obtained from all participants or authorized representatives after extensive description of the ADNI according to 
the 1975 Declaration of Helsinki33. The study was approved by the institutional review boards of all participating 
centers (Ocean University of China, Qingdao Municipal Hospital, Nanjing First Hospital, Memory and Aging 
Center in University of California, and ADNI) and written informed consent was obtained from all partici-
pants or authorized representatives. In addition, the methods were carried out in accordance with the approved 
guidelines.
Participants. The data used in this study were obtained from the ADNI database (http://adni.loni.usc.
edu) Inclusion criteria for AD subjects is National Institute of Neurological and Communication Disorders/
Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD, with a Mini 
Mental State Examination (MMSE) score between 20 and 26, a global Clinical Dementia Rating (CDR) of 0.5 or 
1, a sum-of-boxes CDR of 1.0 to 9.0. All amnestic MCI subjects fulfilled a MMSE score of 24 to 30 and a Memory 
Box score of at least 0.5. Otherwise, the subjects who had any serious neurological disease other than possible AD, 
or any history of brain lesions or head trauma, or were psychoactive medication user (including antidepressants, 
neuroleptics, chronic anxiolytics, or sedative hypnotics) were excluded. More details concerning the ADNI cohort 
were reported elsewhere32,34. The final dataset for the present analysis comprised 812 individuals, including 281 
health controls (normal cognition, NC), 483 MCI and 48 AD at baseline. The basic data of subjects in our analysis 
was downloaded from the ADNI website in 2015.
Genetic data and SNP selection. Bead Studio 3.2 software and a recent Genome Studio v2009.1 
(Illumina) were successively used to generate SNP genotypes from bead intensity data35. Additionally, the widely 
used PLINK data format was accessible to facilitate analysis by other groups. In our study, PICALM genotypes 
were extracted from the ADNI PLINK data format and the quality control procedures were performed using 
PLINK software. Filtering criteria applied to individuals and SNPs were as follows: minimum call rates > 90%, 
minimum minor allele frequencies (MAF) > 0.05, Hardy-Weinberg equilibrium test P > 0.001 (Table 2).
SNPs reported to be significantly associated with AD by GWASs9,10,12 were preferentially selected for analysis. As 
supplementary strategy, we further searched the potentially promising PICALM SNPs from meta-analysis and rep-
lication studies15,36–39. A total of 22 SNPs (Supplementary Table 1) were initially identified in the initial screening, 
among which 15 SNPs were further excluded, including 12 not found in ADNI and 3 with a MAF < 0.05 (Fig. S1). 
Finally, we chose the remaining 7 loci as our target SNPs in this study (Table 2).
MRI structure. ADNI MRIs were acquired at multiple sites with a GE Healthcare (Buckinghamshire, 
England), Siemens Medical Solutions USA (Atlanta, Georgia), or Philips Electronics 3.0 T system (Philips 
Electronics North America; Sunnyvale, California)40. These analyses utilized the dataset of UCSF FreeSurfer to 
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conduct association test of PICALM genotypes with brain structure. We processed the cerebral image segmenta-
tion and analysis using the FreeSurfer version 5.1.0 software package (http://surfer.nmr.mgh.harvard.edu/) based 
on the 2010 Desikan-Killany atlas41. The main work contained that motion correction and averaging of multiple 
volumetric T1-weighted images (when more than one is available)42, removal of non-brain tissue using a hybrid 
watershed/deformable surface algorithm43, automated Talairach transformation, segmentation of the subcortical 
white matter and deep gray matter volumetric structures (including hippocampus, amygdala, caudate, putamen, 
ventricles)44,45, intensity normalization46, tessellation of the gray matter white matter boundary, automated topol-
ogy correction47, and surface deformation following intensity gradients to optimally place the gray/white and 
gray/cerebrospinal fluid (CSF) borders at the location where the greatest shift in intensity defines the transition to 
the other tissue class48. More detailed technical procedures were available in previous study48.
Here, we defined seven brain regions, including hippocampus, hippocampus CA1 subregion, middle temporal 
area, entorhinal area, posterior cingulate, precuneus and parahippocampal area, as regions of interest (ROIs). 
These regions were known to be affected by AD and their atrophy in AD has been previously validated via MRI 
studies49–53. In the present analysis, there were 812 (NC = 281, MCI = 483, AD = 48) individuals included in the 
regional volume/thickness analysis (Table 1).
Statistical analysis. Differences in continuous variables were examined using one-way analysis of variance 
(ANOVA), and categorical data were tested using chi-square test. Furthermore, a multiple linear regression model 
which considered age, gender, education, intracranial volume and ApoE4 status as covariates was used to estimate 
the possible correlation between volume/thickness (baseline data and follow-up changes) and PICALM geno-
types. All statistical analyses were performed by R 3.12 (http://www.r-project.org/) and PLINK 1.07 (http://pngu.
mgh.harvard.edu/wpurcell/plink/). As Bonferroni correction was inappropriate owing to the nonindependence 
of tests40, we used the false discovery rate (FDR), the method developed by Hochberg and Benjamini54, to control 
for multiple hypothesis testing. The criterion for significant difference was P < 0.05 according to FDR correction.
We first screened significant brain regions associated with PICALM loci in the mixed population comprising 
individuals with normal cognition (NC), mild cognitive impairment (MCI) and Alzheimer’s disease. To fur-
ther validate the hereditary susceptibility in different population, we then repeated the test independently using 
sub-population, including NC and MCI and AD individuals.
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